Non-invasive Temporal Interference Stimulation of the Hippocampus
Suppresses Epileptic Biomarkers in Patients with Epilepsy: Biophysical
Differences between Kilohertz and Amplitude Modulated Stimulation

Florian Missey[1,2§], Emma Acerbo[3,4§], Adam S. Dickey[4], Jan Trajlinek[1], Ondřej Studnička[1], Claudia
Lubrano[1], Mariane de Araújo e Silva[1], Evan Brady[4], Vit Všianský[5], Johanna Szabo[6], Irena Dolezalova[5],
Daniel Fabo[6], Martin Pail[5], Claire-Anne Gutekunst[3], Rosanna Migliore[7], Michele Migliore[7,8], Stanislas
Lagarde[2,9], Romain Carron[2,10], Fariba Karimi[11], Raul Castillo Astorga[13], Antonino M. Cassara[11], Niels
Kuster[11,12], Esra Neufeld[11], Fabrice Bartolomei[2,9], Nigel P. Pedersen[13], Robert E. Gross[3,14] , Viktor
Jirsa[2], Daniel L. Drane[4,15,16], Milan Brázdil[5], Adam Williamson[1,17*]

[1]International Clinical Research Center, St. Anne's University Hospital Brno, 60200 Brno, Czech Republic; [2]Aix-Marseille Université,
Inserm, Institut de Neurosciences des Systèmes (INS) UMR_S 1106, Marseille, France; [3]Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Georgia, USA; [4]Department of Neurology, Emory University School of Medicine, Atlanta, Georgia, USA;
[5]Brno Epilepsy Center, 1st Department of Neurology, St. Anne's Univ. Hospital and Faculty of Medicine, Masaryk University, member of
the ERN EpiCARE. 60200 Brno, Czech Republic; [6]Institute of Neurosurgery and Neurointervention, Semmelweis University, Budapest,
Hungary; [7]Institute of Biophysics, National Research Council, Palermo, Italy;[8]SUNY Dept. of Neurology, Downstate Health Science
University, Brooklyn, NY, USA; [9]APHM, Timone Hospital, Epileptology Department, Marseille, France; [10]Department of Functional and
Stereotactic Neurosurgery, Timone University Hospital, Marseille, France; [11]Foundation for Research on Information Technologies in
Society (IT'IS), Zurich, Switzerland; [12]Department of Information Technology and Electrical Engineering, Swiss Federal Institute of
Technology (ETH), Zurich, Switzerland. [13]Department of Neurology, School of Medicine and Center for Neuroscience, University of
California, Davis, CA USA; [14]Department of Neurosurgery, New Jersey Medical School and Robert Wood Johnson Medical School,
Rutgers University, New Jersey, USA; [15]Departments of Pediatrics, Emory University School of Medicine, Atlanta, GA USA; [16]Department
of Neurology, University of Washington School of Medicine, Seattle, WA USA; [17]Center for Social and Affective Neuroscience, Department
of Biomedical and Clinical Sciences, Linköping University, Sweden

§co-first authors, contributed equally   correspondence: adam.williamson@fnusa.cz

Abstract

Medication-refractory focal epilepsy creates a significant challenge, with approximately 30%
of patients ineligible for surgery due to the involvement of eloquent cortex in the epileptogenic
network. For such patients with limited surgical options, electrical neuromodulation represents
a promising alternative therapy. In this study, we investigate the potential of non-invasive
temporal interference (TI) electrical stimulation to reduce epileptic biomarkers in patients with
epilepsy by comparing intracerebral recordings obtained before, during, and after TI
stimulation, to recordings during low and high kHz frequency (HF) sham stimulation.
Thirteen patients with symptoms of mesiotemporal epilepsy (MTLE) and implanted with
stereoelectroencephalography (sEEG) depth electrodes received TI stimulation with an
amplitude modulation (AM) frequency of 130Hz (Δf), where the AM was delivered with lower
frequency kHz carriers (1kHz + 1.13kHz), or higher frequency carriers (9kHz + 9.13kHz),
targeting the hippocampus – a common epileptic focus and consequently stimulation target in
MTLE. Our results show that TI stimulation yields a statistically significant decrease in interictal
epileptiform discharges (IEDs) and pathological high-frequency oscillations (HFOs) –
specifically fast-ripples (FR) –, where the suppression is apparent in the hippocampal focus
and propagation from the focus is reduced brain-wide. HF sham stimulation at 1kHz frequency
also impacted the IED rate in the cortex, but without reaching the hippocampal focus. The HF
sham effect diminished with increasing frequencies (2, 5, and 9kHz, respectively), specifically
as a function of depth into the cortex. This depth dependence was not observed with the TI,
independent of the employed carrier frequency (low or high kHz). Furthermore, a strong carry-
over effect, i.e., suppression of epileptic biomarkers for a period of time after the end of
stimulation, was observed for TI but not for kHz. Our findings underscore the possible
application of TI in epilepsy, as an additional non-invasive brain stimulation tool, potentially
offering opportunities to assess brain region response to electrical neuromodulation before
committing to a deep brain stimulation (DBS) or responsive neurostimulation (RNS) implants.
Our results further demonstrate distinct biophysical differences between kHz and focal AM
stimulation.

Keywords: Temporally Interfering Electric Fields, Non-Invasive Brain Stimulation,
Neuromodulation, Epileptic Biomarkers, sEEG, Amplitude Modulation, Conduction Block

Graphical Abstract

Introduction

Epilepsy presents a significant neurological challenge, as the origins of seizure generation in the brain are highly patient-specific, limiting initial treatment options to generalized medications which lack targeted precision[1]. Additionally, one-third of patients with seizures are drug-resistant, leaving resective surgery as the primary treatment option[2]. However, approximately 30% of drug-resistant patients are not suitable candidates for resective surgery due to the high functional importance of areas necessitating resection[2]. In such cases, invasive brain stimulation – specifically deep brain stimulation (DBS) or responsive neurostimulation (RNS) – is typically the remaining therapeutic option[3]. Alternative neuromodulation treatments, such as Vagus Nerve Stimulation (VNS), are available for drug-resistant epilepsies but generally do not achieve complete seizure freedom[4–7].

Both DBS and RNS are challenging, as there are numerous potential targets (e.g., anterior nucleus of the thalamus - ANT, centromedian nucleus of the thalamus - CMT, pulvinar, hippocampus, and neocortex)[8–12], and only a small number of targets (notably the ANT, CMT and hippocampus) have been thoroughly evaluated in double-blinded studies. DBS stimulation at 130-145Hz of either the hippocampus or ANT resulted in a reduction of seizure frequency[10–14], along with a decrease in interictal epileptiform discharges (IEDs) in temporal lobe epilepsy patients[15,16,17,18]. A motivation for our study is that a subset of patients do not respond favorably to DBS or RNS and can suffer cognitive side effects, which are difficult to predict ahead of implantation[19–21].

Non-invasive brain stimulation techniques targeting these regions identified as suitable DBS or RNS locations, could support the prediction of post-implant side effects prior to invasive implantation. The most common non-invasive techniques include transcranial alternating current stimulation (tACS), transcranial direct current stimulation (tDCS), and transcranial magnetic stimulation (TMS) – techniques with applications in both research and clinical practice[22]. The methods modulate brain activity via electric currents delivered through the scalp and skull, or induced magnetically, and influence neuronal excitability, connectivity, and plasticity, ultimately leading to changes in brain function[23]. However, efficacy of traditional non-invasive methods in the treatment of epilepsy is limited, and the methods are typically considered applicable only to shallower cortical targets and not to the deep structures associated with therapeutic invasive DBS[24].

Temporal Interference (TI) stimulation is an emerging non-invasive electrical stimulation
technique which allows electrical modulation of deep brain structures. Unlike traditional
methods, TI applies high frequency currents (>1kHz) using a minimum of two independent
pairs of transcutaneous stimulation electrodes. The employed frequencies differ slightly,
resulting in an amplitude-modulated field because of alternating phases of constructive and
destructive interference. The kHz current pathways are optimized to maximally and selectively
amplitude-modulate the field at a specific deep brain target where the fields overlap[25]. The
amplitude modulation (AM) frequency is equal to the frequency difference ($\Delta f = |f1 - f2|$). When
Δf is in the physiological range, there is evidence that neural activity is modulated. Notably,
the frequency of the AM in previous experiments has been selected to match conventionally
applied DBS frequencies to produce similar effects[26]. TI has been tested in rodent[27–32] and
non-human primate[33] models, and more recently, in healthy human subjects[34].
We have previously employed TI stimulation using a 130 Hz envelope frequency, a frequency
often used for invasive DBS in epilepsy patients and in epileptic animal models, and known to
suppress epileptic biomarkers[27].
In this work, we analyzed the impact of TI with a 130Hz AM signal in patients with epilepsy.
Patients implanted with stereoelectroencephalography (sEEG) depth electrodes were
hospitalized for 2 to 3 weeks to assess potential resective surgery targets. sEEG electrodes
are implanted to record intracranial electrophysiological signals and stimulate precise deep
brain areas in order to assist in the delineation of the epileptogenic zone (EZ) and its relation
with eloquent cortices. Utilizing recordings from the sEEG electrodes during TI, we were able
to investigate alterations in epileptic biomarkers as a function of TI stimulation (Δf=130Hz
frequency modulation) and to map the applied AM signal in order to ascertain its hippocampal
focality. The study has taken place at three research centers, Emory University (USA), St.
Anne's University Hospital (Czech Republic), and Semmelweis University (Hungary).
Our results demonstrate that TI stimulation significantly decreases interictal epileptiform
discharges (IEDs) and pathological high-frequency oscillations (HFOs) – specifically fast-
ripples (FR) – within the hippocampal focus and reduces propagation across the brain. In
contrast, sham stimulation at lower kilohertz (kHz) frequencies impacted cortical but not
hippocampal IEDs, with diminishing effectiveness at increasing kHz frequency. Furthermore,
a therapeutic carrier-over effect – the suppression of epileptic biomarkers for a period of time
after the end of stimulation – was only observed for AM and not for unmodulated kHz. The
results suggest distinct differences in biophysical mechanisms and associated response
characteristics from kHz compared to focal AM.
129
130 **Methods**
131
132 *The study is registered as a clinical trial with clinicaltrials.gov (NCT06716866).*
133
Patients: 13 patients with drug-resistant focal epilepsy and a clinical diagnosis of medial
temporal epilepsy participated in the study after providing informed consent. All procedures
involving human participants were conducted following the ethical standards of the institutional
and/or national research committee (IRB00099109 Emory University, IIT/2023/25 Saint-Anne
University Hospital - SAUH, OGYÉI/56526-2/2023 Institute of Neurosurgery and
Neurointervention, Semmelweis University - INN-SU) and in accordance with the 1964
Helsinki Declaration and its later amendments or comparable ethical standards. All
participants underwent video-EEG characterization of seizures and either 1.5 or 3 Tesla MRI,
and PET scans in some patients. Presurgical non-invasive examinations, including high-
resolution MRI scans, were performed to assess patient eligibility. Intracerebral multi-contact
electrodes (Alcis® - INN-SU, Hungarian center; Dixi® - Emory University, USA center and
SAUH, Czech center; 10-18 contacts) were surgically implanted for sEEG exploration.
Postoperative computed tomography (CT) scans and/or MRI scans were conducted to verify
the absence of complications and ensure accurate electrode placement using the GUI-based
open-source application GARDEL[35]. Across all centers, patients underwent the stimulation
protocols 6 to 10 days post-implantation.

<u>Modeling and simulations</u>: Finite element simulations were executed utilizing both Sim4Life
and the Sim4Life TI Planning Tool software developed by Zurich MedTech AG to estimate
temporal interference stimulation. The simulations solved the ohmic-current-dominated
electro-quasistatic equation $\nabla(\sigma\nabla\phi) = 0$. Here, σ denotes the local electrical conductivity, ϕ the
electric potential, and the E-field is obtained as $E=-\nabla\phi$. The ohmic-current-dominated electro-
quasistatic approximation of Maxwell's equations is suitable because $\sigma \gg \omega\epsilon$ (ω: angular
frequency, ϵ: permittivity, i.e., ohmic currents dominate over displacement currents) and the
wavelength is much larger than the domain size.
The human model utilized in the Sim4Life simulations was derived from patient-specific MRI
scans (co-registered T1 and CT). The head model for each patient included the associated
implanted sEEG electrodes. All patients had the sEEG locations included in the model for
postprocessing. However, only the patients from the FNUSA center had the sEEG electrodes
properly modeled with recording contacts as Perfect Electrical Conductors (PEC) and inter-
contacts as insulators. Tissue and electrode conductivities were automatically allocated to the
model based on the ITI'S Foundation tissue properties database[36] (low-frequency
conductivities section). Stimulation electrodes mirrored the shape of the gel-based electrodes
used in human experiments. Simulation results were normalized to total current, after applying
Dirichlet boundary conditions at active electrodes. Equation 1 from Grossman et al., 2017[25],
was used to calculate the maximum modulation amplitude:

$$\left|\vec{E}^{max}_{AM}(\vec{r})\right| = 2\left|\vec{E_2}(\vec{r})\right| \quad if \quad \left|\vec{E_2}(\vec{r})\right| < \left|\vec{E_1}(\vec{r})\right|\cos\alpha$$

Otherwise

$$\left|\vec{E}^{max}_{AM}(\vec{r})\right| = \frac{2\left|\vec{E_2}(\vec{r})\times\left(\vec{E_1}(\vec{r})-\vec{E_2}(\vec{r})\right)\right|}{\left|\vec{E_1}(\vec{r})-\vec{E_2}(\vec{r})\right|}$$

Equation 1. Maximum amplitude modulation formula.

176 <u>Recordings</u>: All studies were conducted with participants in the waking state. sEEG signals
177 were recorded digitally (1024 or 2048 Hz, Natus Medical Incorporated®, Emory), or with a
178 BioSDA09 (25 kHz, M&I, spol. s r.o.®, INN-SU and SAUH). The latter has an input signal
179 voltage of +/- 25 mV, with an optional hardware filter of 0.01 Hz - 10 kHz), which allows to
180 monitor stimulation voltages (sEEG artifact) during TI or sham stimulation.
181
<u>Stimulation (TI/sham)</u>: Stimulation was applied to target the mesial temporal lobe with the
target centered on the head of the hippocampus given that most IEDs originated from the
hippocampus and the hippocampal formation was part of the epileptogenic network from which
seizures originated.
TI stimulation was performed using two DS5 devices (Digitimer®, UK) driven by a function
generator (Keysight®). Scalp electrodes (circular-shaped gel-assisted ECG electrodes,
Ag/AgCl, 0.8 cm diameter, Ambu® or FIAB®) were used for TI stimulation. They were placed
according to *Violante et al.*[34] to target the hippocampus and in accord with Sim4Life modeling.
Frequencies of TI stimulation varied among centers: Emory used 1300 and 1430 Hz, and the
Czech and Hungarian centers 9000 and 9130 Hz, applying ±2 mA per pair (4 mA peak-to-
peak). There were two protocols: In the first (SAUH and FNUSA), 20 minutes of baseline
recording, followed by either sham stimulation (day one at SAUH and FNUSA), or active TI
(day two), followed by 20 minutes of recording after the cessation of TI (see Figure 2A). At
Emory University, all participants underwent 20 minutes of baseline, 20 minutes of
sham/active TI and 20 minutes of post-TI recording (day one and two), with an additional
recording of 20 minutes on day three. In the sham condition, the same carrier frequency was
applied to both channels (Δf=0Hz, same current magnitudes as applied in the TI session),
such that no amplitude modulation resulted. In the active TI condition, there was an offset
frequency of 130 Hz - a typical frequency used for neuromodulation in epilepsy.
201
<u>AM Analysis</u>: Gardel was used to accurately localize sEEG electrode contacts. Briefly, the T1
MRI was co-registered with the post-implantation CT and electrodes were labeled. For the
analysis of TI waveforms, the recorded signal underwent bandpass filtering (1 kHz - 10 kHz).

The AM magnitude was computed using the Hilbert transformation of the filtered signal. A
sliding window of 230ms was employed to determine the peak-to-peak amplitude of the AM in
mV by subtracting the minimum from the maximum AM values. The median value across all
windows was utilized as the amplitude value for each contact. This process was conducted
for each contact, providing amplitude values per contact (the reference was set as the
averaged signal from all the electrodes in the brain). Finally, the amplitude values were
projected onto the electrodes within the anatomical mesh of the patient to visually assess
which brain regions received stimulation (Figure 1B).

Biomarkers Detection: For the detection of biomarkers, electrophysiological signals were
filtered (lowpass filtering [<1000Hz], performed using Matlab - MathWorks) to remove the
stimulation artifacts. After down-sampling to 2500 Hz, semi-automatic detection of IEDs and
HFOs (ripples and fast ripples) was performed using the AnyWave's validated Delphos
detector [37] – a well-established IED and HFO detector, regularly used in clinical epilepsy
research[38]. Events markers (IEDs, HFOs) were extracted to determine their rates per minute.
Subsequently, detected events were manually validated using AnyWave, a visualization
software for electrophysiological data[37].

Statistics: The results of the detection process were imported into MATLAB (MathWorks), to
facilitate comprehensive analysis and statistical assessment, and organized into distinct
matrices based on patient identifiers, treatment centers (EMORY, INN-SU, or SAUH), and
protocol conditions (baseline, stimulation, sham, post, and post 24H). From these matrices,
initial visualizations were generated for each patient before aggregation for inter/intra-patient
and inter/intra-center statistical assessments. IED, ripple ([80 250]Hz), and FRs ([250 500]Hz)
rates were computed and juxtaposed across different stimulation protocols, as illustrated in
Fig. 2, employing multivariate analysis of variance (ANOVA or Friedman test) and paired T or
Mann-Whitney-Wilcoxon tests to discern significant variations. The aggregated dataset
underwent further comparison via Friedman ANOVA and paired Wilcoxon tests to identify
potential differences across all experimental conditions.

Single neuron modeling: To study the interaction between a hippocampal CA1 pyramidal
neuron and electrical fields we used a previously published model[39,40], available online on the
ModelDB database (a.n. 151731 and 190559, respectively). A detailed morphological and
biophysical reconstruction of a CA1 pyramidal neuron[41] (cellc62564 from Migliore *et al.* (2008),
ModelDB a.n. 87535) was used for all simulations. A first set of simulations was performed in
current clamp mode, injecting one or two currents for 1 sec and implemented as Equation 2
at different amplitudes I_0.

$I_{inj} = I_0 \sin \sin [2\pi f(t - t_0)]$ or $I_{inj} = I_0 \sin \sin [2\pi f(t - t_0)] + I_0 \sin \sin [2\pi(f + f_{off})(t - t_0) + \varphi])$

Equation 2. Injected current formula.

All simulations were performed using v.8.2.2 of the NEURON simulation environment (Hines
and Carnevale, 1997)[42].

Results

Temporal Interference Protocol in sEEG-implanted Epilepsy Patients

TI stimulation was performed in patients with drug-resistant mesial temporal lobe epilepsy
implanted with sEEG electrodes (Figure 1A). Epilepsy patients with implanted sEEG
electrodes offer a unique opportunity to precisely delineate the stimulated zone and assess
the impact of TI exposure on brain activity. sEEG electrodes recorded the electrophysiological

signal changes evoked by TI and mapped the AM exposure from the TI stimulation. The setup involved the placement of four scalp electrodes (2 pairs of 2 electrodes) to deliver TI stimulation, which consisted of two high-frequency signals unilaterally targeting the hippocampus (the side of the epileptogenic network) (Figure 1A and B).

Figure 1. Temporal interference protocol in sEEG-implanted patients with epilepsy. (**A**) Scalp electrodes were positioned to deliver TI stimulation, consisting of two high-frequency currents which produce an AM field targeting the hippocampus in the temporal lobe. sEEG electrodes simultaneously record the electrophysiological signal and the modulated TI stimulation signal. Timeline of the experiments performed at the three centers: Admission Day 0, Stimulation Days 8-9. Each center applied TI with an AM frequency Δf = 130Hz, during a 20-minutes stimulation session and recorded the brain signal response after stimulation. (**B**) **Patient-specific head model and AM signal from TI stimulation.** MRIs of patients were used to create patient-specific head models using Sim4Life. (Top panel) the example simulation shows the placement of stimulation electrodes (red/blue) to target the ipsilateral hippocampus. The green border depicts an isocontour of the AM electric field, indicating the highest region of modulation centered on the hippocampus. (Bottom panel) simulations compare well to intracranial data, which similarly shows maximum AM in the temporal lobe (electrodes A, B, C), specifically in the hippocampus. Example recordings from the middle contacts of electrode C are shown. The raw signal (with using the average of all intracranial signals as reference) during TI stimulation allows visualization of the amplitude of the AM signal. When zooming in, the stimulation artifact revealed a well-defined AM in the deepest contacts, with diminishing magnitude approaching the cortex. The exact same recordings during TI stimulation are shown filtered with a bandpass filter ([1-1000] Hz) to extract electrophysiological signals. All oscillations below 500Hz were recovered, and reduced interictal spiking activity was observed for the TI condition.

Simulation and Visualization of Stimulation Site

As seen in Figure 1B (top panel), an MRI image of a patient with stimulation electrodes specifically targeting the ipsilateral hippocampus is seen. The associated patient-specific simulation of the TI exposure targeting the hippocampus is visualized using Sim4life. The simulation estimates the electrode position for a correct stimulation of the hippocampus and delineates the region of strong AM modulation (green border) within the temporal region - with the maximum modulation located in the patient's hippocampus.

Recordings of AM Potential

An example sEEG recording of the AM potential during TI stimulation can be seen in Figure 1B (bottom panel). The amplitude of the AM was extracted and is depicted on the contacts of

each sEEG electrode in the figure. The highest AM was observed on the electrodes within the temporal lobe, specifically in the hippocampus, and showed good agreement with the patient-specific Sim4Life simulations. The AM magnitude progressively diminishes towards more superficial cortical regions, while the magnitude of the carrier increases. An analysis of the filtered signal (1-1000 Hz) demonstrated the ability to extract electrophysiological signals (IEDs/HFOs), as TI stimulation artifacts are generally several thousand Hz higher than the electrophysiological signal of interest. No IEDs are visible in the example recording.

Epileptic Biomarker Suppression with TI

All patients underwent baseline, stimulation, and post-stimulation recordings (see Figure 2A) consisting of 20 minute blocks: baseline recording, TI stimulation, post-stimulation recording (in the 20 minutes after the stimulation), and (at FNUSA only) an additional post-stimulation recording 24 hours after the stimulation session. During TI stimulation, patients did not report any symptoms, such as sensations associated with TI stimulation on the scalp, or other subjective symptoms with frequencies centered at 9kHz; 2 patients out of 3 receiving TI at 1/1.13kHz felt tingling on the scalp without any adverse events. There were no adverse events.

Figure 2. Epileptic biomarkers are suppressed during TI stimulation, and a post-stimulation carrier-over effect is observed. (**A**) The stimulation protocol was the same across the different centers (USA, Czech Republic, Hungary). Center-to-center differences are shown in Supplemental Figure S1. The protocol includes baseline recording (20 minutes), TI stimulation protocol (20 minutes; 30-second ramp-up and 30-second ramp-down included), post-stimulation recording (20 minutes), and – only in Czech Republic – post-24-hour recording (20 minutes). (**B**) Analysis of IEDs rates by brain region. All regions show a decrease in IED rate during TI stimulation. Analysis comparing all biomarker rates across all centers from the mesial temporal focus (n.s: p-value > 0.05 ; *: p-value ≤ 0.05; **: p-value ≤ 0.01; ***: p-value ≤ 0.001). (**C**, **D**, and **E**) Looking at the epileptic focus in detail: TI stimulation significantly decreases IEDs, ripples, and FRs , in a way similar to responses in DBS studies[40,41]. A feature of the TI biomarker suppression is that, in addition to the suppression during stimulation, the biomarkers do not return to their pre-stimulation values in the 20-minute period after stimulation – the suppression has a strong carrier-over effect. The 24-hour recordings indicate that the suppression is not permanent, seeing that biomarkers have returned to their pre-stimulation values. Brain-wide suppression of IEDs is a good indication that the focus of the epilepsy (the location of spike generation; in these patients the mesial temporal region, specifically the hippocampus) has been suppressed. (**F**) As the focus was suppressed, we expected and observe limited generation and therefore limited propagation of IEDs and HFOs. (**G**) The simultaneous suppression of HFOs and IEDs is understood via co-occurrence: it is well-known that HFOs strongly co-occur within IEDs[43,44]. This co-occurrence also appears in our data.

We compared the distribution of IEDs detected by sEEG in various brain regions (see Figure 2B): the whole brain (all SEEG contacts), the temporal lobe (electrodes A,B,C, and P from the

most impaired side), the temporo-mesial area (deep contacts – 1 to 7 – from electrodes A,B,C, and P from the most impaired side)(the hippocampal focus), and the temporal cortex (shallow contacts – 8 to 15 – from electrodes A,B,C, and P from the most impaired side). All analyses were realized with the 'global group' encompassing all patients from the three centers. In baseline recordings, all patients showed signs of temporal lobe epilepsy, with a mesial focus. TI stimulation produced a statistically significant decrease in IEDs rate across all brain regions, which suggests that the focus was suppressed (IEDs originating from an unsuppressed additional focus would be visible). Post-stimulation data shows a strong carry-over effect with IEDs not returning immediately to baseline values. The post-stimulation recording 24 hours later shows that the IED rate returned to the baseline level, the carry-over effect is not permanent.

Specific analysis of TI's impact on the epileptic biomarkers (IEDs, ripples, and FRs), specifically in the temporo-mesial region with the hippocampal focus, is presented in Figure 2C, D, and E. All epileptic biomarkers were statistically decreased during TI stimulation in the focus compared to the baseline recordings (Friedman ANOVA, p-value < 0.0001). In all three centers, TI stimulation of the mesial temporal lobe was correlated with a decrease in IEDs (data for each participating center in supplemental figures). The relative decrease ranged up to 86.3% (58.5 +/- 27.8%, IC95%) depending on the patient (Friedman ANOVA, $p\text{-value}_{TI\ stimulation\ vs.\ baseline}$ < 0.0001).

For HFOs, it is well established that excessive pathological ripples[43] and pathological fast ripples[44] co-occur within IEDs (see Figure 2G). Our data shows a reduction of IEDs with a corresponding reduction of co-occurring HFOs[45,46].

For all three centers, the stimulation effect was sustained, as evidenced by a significant decrease in IEDs and HFOs 20 minutes after stimulation (Wilcoxon tests, $p\text{-value}_{Post\text{-}stimulation\ 20\ minutes\ vs.\ baseline}$ < 0.0001). TI stimulation (Figure 2F; purple) targeting the pathological mesial focus (orange) shows a strong suppression of epileptic biomarkers, and a suppression of the propagation of biomarkers, with a sustained post-stimulation carry-over effect.

Epileptic Biomarkers Suppression with kHz (Sham) Stimulation

As TI is delivered via a combination of kHz frequencies, we investigated the effect of sham stimulation, where both pairs of electrodes provide the same frequency, and no offset is present between f1 and f2 (Figure 3A).

As seen in Figure 3A, all sham patients underwent the same protocol in blocks of 20 minutes: a baseline recording, kHz sham stimulation (two pairs of electrodes with no offset frequency – applying the same currents as for TI stimulation), and a post-stimulation recording (for 20 minutes after stimulation). The electrode locations were also identical to the TI stimulation electrode locations. Patient-specific Sim4Life simulations were performed to determine the carrier field magnitude distribution. The illustrative visualization in Figure 3B delineates the region of maximum kHz exposure (top panel), situated in the temporal region, and the expected absence of AM (middle panel). sEEG electrodes were used to record the electrophysiological signal changes evoked by sham and to map the sham exposure potential (bottom panel). The example recording features IEDs in the mesial focus (highlighted by red arrow), but not in the cortex where there is a higher kHz field magnitude.

Figure 3. Sham stimulation and HFO suppression. Sham stimulation consisted of applying the same frequency
($f_1 = f_2$) to both pairs of electrodes. The protocol is 20 minutes baseline recording, 20 minutes sham stimulation and
recording, and 20 minutes post-stimulation recording. A 30-second ramp-up and a 30-second ramp-down is
included to avoid unwanted transients. The stimulation amplitude is ±2mA (4mA peak-to-peak) (**A**). As for the TI
stimulation condition, a patient-specific simulation is performed to estimate the kHz field strength and illustrate the
absence of AM. The sham voltage recorded by sEEG in a patient is visualized. After filtering, example IEDs (red
arrows) are apparent in the hippocampus recordings, but not in the cortical ones (**B**). The changes in biomarker
rate between baseline and sham stimulation are plotted as a function of location along the ipsilateral sEEG
electrode entering the pathological hippocampus. The zero line (dashed line) and grey region denote the absence
of a significant rate difference between baseline and sham. sEEG contact locations in the epileptic focus are
highlighted in purple. A biomarker rate reduction of over 20% is considered a clear indication of sham suppression.
As can be seen, suppression penetrates the deepest at 1kHz. At 9kHz change remains below ±20% throughout
for all biomarkers (**C**, **D**, **E**). Biomarkers are plotted for the three parts of the sham protocol using the lateral cortical
contacts – sEEG contacts 15 to 8 (**F**, **G**, **H**). 1 kHz caused a significant suppression during stimulation, potentially
due to conduction block. 9 kHz did not cause significant suppression. In each case, there was no visible carrier-
over effect, unlike in the TI conditions.

The effects of kHz sham on biomarker rates are shown in Figure 3C, D, and E, as a function
of depth along the sEEG electrode into the ipsilateral hippocampal focus. IEDs, ripples, and
FRs rate changes are pictured in C, D, and E respectively. Fluctuations outside of the ±20%
range are considered a clear indication of kHz suppression of a biomarker, rather than
physiological variations between the two 20-minute sessions of baseline and sham[47]. Vertical
dotted lines represent the depth at which the sham stimulation starts to decrease the
biomarkers. For the considered electrodes, contacts #15 – #10 are located in lateral cortices
and contacts #9 – #1 are in the medial cortices (including hippocampus).
Higher frequencies (i.e. 7 and 9 kHz) show less biomarker reduction compared to lower carrier
frequencies (i.e. 1 and 2 kHz) in the superficial cortices. Lower frequencies are, furthermore,
associated with deeper penetration of rate changes. 9kHz sham minimally impacts these
biomarkers.
As shown in detail for 1kHz and 9kHz in Figure 3 F, G, and H, a common trend is visible across
all biomarkers: sham-stimulation induced decreases in IEDs and HFOs (ripples and fast
ripples) at lower kHz frequencies in the lateral, but not deeper medial cortices/hippocampus,
and had no significant decrease at 9kHz. Additionally, for low-frequency kHz biomarker
suppression, there is no measurable carry-over effect.

Previous studies using simulations of injected charge with a Hodgkin-Huxley (HH) axon model
have suggested kHz conduction block as a possible side-effect of TI deep brain modulation[48].

Specifically, models predict that a deep brain region may respond to the AM signal, but
shallower brain regions will be subjected to stronger kHz fields which may lead to conduction
block. Although perhaps not "conduction block" in the traditional sense of suprathreshold
stimulation of peripheral nerves, we believe that we have observed a similar phenomenon
when using lower frequency kHz carriers for TI, and as predicted by the models, the
phenomenon diminishes as the kHz frequencies increase further - as neural activation
thresholds increase with kHz frequency (Figure 4B). To avoid the phenomenon, one can use
a higher carrier frequency. However, some models predict that shifting the carrier frequency
up (while maintaining Δf constant) to reduce conduction block, will simultaneously reduce the
modulatory effectiveness of AM. We do not observe this experimentally. More precisely (deep
contacts – 1 to 7 – from electrodes A, B, C, and P from the most impaired side), we did not
see any reduction in the effectiveness of epileptic biomarker suppression by using higher
carrier frequencies when comparing the biomarker rates during TI stimulation (Wilcoxon tests,
p-value$_{TI1000Hz \ vs \ TI9000Hz}$ > 0.05).
459
Overall, these results suggest that TI stimulation can reduce HFOs and IEDs, when targeting
the hippocampus with a modulation at a traditionally inhibitory frequency (130 Hz). For sham,
mid/low-carrier frequencies (≤ 5kHz) also decrease the number of epileptic biomarkers, but
only in superficial cortices. With a 130 Hz AM, the highest carrier frequency we tested (9 kHz)
caused a significant decrease in all epileptogenic biomarkers, while the corresponding sham
condition, did not change ripple and fast ripple rates, and had the least effect on IEDs. The
carrier frequency selection seems to play an important role for the use of TI as a focal, non-
invasive form of deep brain modulation, i.e. 9kHz induces less off-target neuromodulation than
1kHz, due to the absence of kHz carrier field effects.
469

Discussion

471
Figure 4. Biophysics Insights. A) Previous work simulating exposure-induced suprathreshold neuromodulation
of a Hodgkin–Huxley-like (HH) axon model has highlighted the potential for conduction block in TI stimulation[48].
Our sham stimulation results are consistent with some of the concerns raised by those authors. **B)** Conductivities
and permittivities implemented in the simulations are based on Gabriel et al., 2009[49]; values can be revised if new
conductance measures become available. The carrier frequency dependence of sham effects cannot be explained
by field magnitude differences, as electrical conductivity hardly depends on frequency below 10 kHz, such that for
identical channel current magnitudes the quasistatic solutions to Maxwell equations are very similar – only at much
higher frequencies does the frequency dependence of conductivity and its impact on displacement currents
become relevant. Also head and contact impedance changes as a function of frequency are fully compensated for
by the current control of the sources (see supplemental figure S5). **C)** Experimental work by Bernard Katz[50] and
simulations with an HH-like neuron model, showed that the threshold for propagation blocking by unmodulated
exposure (red shading) increases with frequency (the threshold obviously depends on diameter, fiber type, etc).
This is in accordance with the kHz suppression (where we use the word suppression and not block, as we apply
subthreshold electric fields) of IED propagation from the mesial focus observed in this study for low kHz sham
frequencies and the experimentally demonstrated decrease in the suppression depth with increasing carrier
frequency (fading red). However, the HH model fails to replicate the experimentally observed absence of a strong
carrier frequency impact on AM effectivity. Moving to a higher carrier frequency eliminated sham effects - however,
the AM signal created with the same higher carrier frequency suppressed the epileptic focus without apparent
reduction in efficacy (purple region). **(D – E).** Support for assuming that two different mechanisms are at work could
be derived from the lack of a carry-over effect from sham stimulation (turning off the high frequency allowed activity
to propagate normally again), while AM exposure produced a strong carry-over effect, where suppression of the
hippocampal focus resulted in a continued reduction of epileptic biomarkers post-stimulation.

Here we show for the first time that a non-invasive deep brain modulation method, Temporal
Interference, can selectively target the epileptic focus and reduce epileptiform activity in
epilepsy patients, as verified by intracerebral EEG recordings. We show that TI can create an
AM signal at depth in the human mesial lobe and that TI stimulation at Δf = 130Hz can
significantly reduce IEDs, ripples, and FRs during stimulation. Furthermore, we show that the
choice of carrier frequencies matters for TI stimulation: As illustrated in Figure 4A and C, our
results are consistent with the presence of biomarker suppression, primarily in superficial
structures, at low kHz frequencies. However, suppression mechanisms explained by high-
frequency conduction block, as well as simple HH models of neural dynamics, fail to explain
how TI with higher kHz carriers produces targeted, non-invasive, deep brain modulation, with
no penalty in terms of effectiveness compared to TI with lower kHz carriers – something that
previous studies had ruled out based on theoretical and computational considerations[51]. This
highlights the importance of clarifying the mechanisms underlying TI neuromodulation.
In terms of future utilization in epilepsy, the application of TI stimulation represents a significant
advancement in the pursuit of non-invasive diagnosis and therapy for epilepsy, particularly for
patients who are not suitable candidates for resective surgery. Unlike conventional
transcranial electrical stimulation techniques, such as tDCS and tACS, which are limited by
the dominance of superficial cortical effects, TI stimulation allows for the modulation of neural
activity in deeper brain structures without invasive procedures. This is particularly relevant for
targeting epileptogenic zones located in areas of the brain which are not easily accessible by
traditional stimulation methods or only by electrical stimulation via depth probes[52,53].
In previous work, TI stimulation in the peripheral[29] and central nervous systems modulates
population-wide neural activity[54] as well as individual neuronal activity[55], when employing Δf
frequencies similar to those found to be effective when applied directly (i.e. Δf = 1Hz
modulating activity at a rate of 1 Hz – as is expected if 1Hz is directly applied). Our findings
here are similarly in line with previous research, namely studies conducted in the hippocampus
of mice in an epilepsy model[27] as well as with various clinical studies which have used DBS
stimulation (130-145Hz) in the hippocampus of patients to manage their seizures and
decrease epileptogenic biomarkers[3,10,13,14,56–58].
Future work could leverage the ability of TI to reduce IEDs non-invasively and in a targeted
manner, as there is growing awareness that IEDs can transiently disrupt focal and global
cognitive processes, and anti-seizure medications are currently not deliverable in a focal
manner[59–62]. In that sense, TI could be a valuable tool in neurological investigation of cognitive
task performance with epilepsy patients. Indeed, even for conduction block, as we observed
for lower kHz frequencies, it is possible that this mechanism could be used beneficially in the
context of epilepsy in future work.
While the presented results are promising, several limitations must be acknowledged. First,
the study's reliance on patients already implanted with sEEG electrodes for epilepsy
monitoring and who feature identifiable seizure foci means that the findings may not be directly
generalizable to the broader population with refractory epilepsy – for example in generalized
seizures, where identification of specific EZs is not possible. Furthermore, we only investigated
medial temporal/ hippocampal and not neocortical EZs, because we aimed at demonstrating
the feasibility of stimulating deep structures, and for the purpose of acquiring sufficient patients
with a similar target given that this is the most common type of epilepsy in adults. Additionally,
the specificity and efficacy of TI stimulation in reducing seizures and seizure frequency
remains to be fully established through longitudinal studies with larger sample populations,
but the benefit of other neuromodulatory therapies correlates with IED suppression.
541
542 **Conclusion**
543
In conclusion, the application of TI stimulation in patients with epilepsy represents a novel and
promising approach to the non-invasive treatment of epilepsy. While preliminary findings are
encouraging, further research is essential to elucidate the potential of TI stimulation to help
manage focal epilepsy, in particular as a tool to assess neurostimulation responses prior to
DBS or RNS implantation.

Future research should expand the number and diversity of studied patients undergoing TI
stimulation, to better understand its efficacy and safety profile across different types of
epilepsy and to assess the long-term impact of stimulation. Additionally, further investigation
into the mechanisms underlying the effects of TI stimulation are required to enhance our
understanding of TI and epilepsy pathophysiology and to be able to systematically optimize
and personalize stimulation parameters in the spirit of precision medicine.

555
556 **Acknowledgments**
557

A.W. received funding from the European Union's Horizon Europe research and innovation
programme under grant agreement No. 101101040 (TREATMENT) and No. 101088623
(EMUNITI). Efforts on this project for both D.L.D. and E.A. were in part supported by grants
received from the National institute of Neurological Disorders and Stroke (NINDS) of the
National Institutes of Health (NIH) [R01NS088748]. E.A. was also supported through the
Emory Neuromodulation Technology Innovation Center (ENTICe) and a Catalyst Award from
the Emory Neurosurgery Department to C.A.G. and D.L.D. E.A. was also supported by the
American Epilepsy Society (AES) post-doctoral fellowship. We thank S. Dabiri for his
assistance in downloading MRI and electrophysiological recordings. We extend our thanks to
the dedicated nurses at the epilepsy units of Emory University, St. Anne's University Hospital,
and Semmelweis University for their invaluable support. This work received financial support
from Agence Nationale de la Recherche under France 2030 bearing the reference "ANR-24-
RRII-0005 », on funds administered by Inserm.

571
572 **Authors Contribution**
573

A.W. conceived and designed the project. F.M., E.A., A.D., J.T., O.S., C.L., M.A.S., E.B., V.V.,
J.S., D.F., conducted human experiments and acquired neural data. F.M. and E.A. analyzed
neural data. F.M. created the patient-specific head models and performed the associated
finite-element models. R.M. and M.M. designed and analyzed single-neuron models. F.K. and
E.N. investigated the implant related field enhancement. F.M., E.A., D.L.D., and A.W. wrote
the first draft of the manuscript and refined it after inputs from I.D., M.P., C.A.G., S.L., R.C.,
F.K., R.C.A., A.M.C., N.K., E.N., F.B., N.P.P, R.E.G, V.J., and M.B.

581
582 **Conflict of Interest**
583
584 N.K. and E.N. are shareholders of TI Solutions AG, a company dedicated to producing
585 temporal interference (TI) stimulation devices to support TI research.

586
587 **Data Availability Statement**
588
589 All data produced in the present study are available upon request to the authors.

References

1. Fiest KM, Sauro KM, Wiebe S, et al. Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies. *Neurology*. 2017;88(3):296-303. doi:10.1212/WNL.0000000000003509

2. Ryvlin P, Cross JH, Rheims S. Epilepsy surgery in children and adults. *Lancet Neurol*. 2014;13(11):1114-1126. doi:10.1016/S1474-4422(14)70156-5

3. Li MCH, Cook MJ. Deep brain stimulation for drug-resistant epilepsy. *Epilepsia*. 2018;59(2):273-290. doi:10.1111/epi.13964

4. Satya-Murti S, Shepard KM, Helmers SL. Vagus nerve stimulation in the treatment of epilepsy. *Neurology Clinical Practice*. 2013;3(5):431-435. doi:10.1212/CPJ.0b013e3182a3931f

5. Ellrich J. Transcutaneous Auricular Vagus Nerve Stimulation. *Journal of Clinical Neurophysiology*. 2019;36(6):437. doi:10.1097/WNP.0000000000000576

6. Toffa DH, Touma L, Meskine TE, Bouthillier A, Nguyen DK. Learnings from 30 years of reported efficacy and safety of vagus nerve stimulation (VNS) for epilepsy treatment: A critical review. *Seizure - European Journal of Epilepsy*. 2020;83:104-123. doi:10.1016/j.seizure.2020.09.027

7. Panov F, Ganaha S, Haskell J, et al. Safety of responsive neurostimulation in pediatric patients with medically refractory epilepsy. *Journal of Neurosurgery: Pediatrics*. 2020;26(5):525-532. doi:10.3171/2020.5.PEDS20118

8. Warren AEL, Dalic LJ, Thevathasan W, Roten A, Bulluss KJ, Archer J. Targeting the centromedian thalamic nucleus for deep brain stimulation. *J Neurol Neurosurg Psychiatry*. 2020;91(4):339-349. doi:10.1136/jnnp-2019-322030

9. Vonck K, Sprengers M, Carrette E, et al. A decade of experience with deep brain stimulation for patients with refractory medial temporal lobe epilepsy. *Int J Neural Syst*. 2013;23(1):1250034. doi:10.1142/S0129065712500347

10. Velasco AL, Velasco F, Velasco M, Jiménez F, Carrillo-Ruiz JD, Castro G. The role of neuromodulation of the hippocampus in the treatment of intractable complex partial seizures of the temporal lobe. *Acta Neurochir Suppl*. 2007;97(Pt 2):329-332. doi:10.1007/978-3-211-33081-4_36

11. Salanova V, Witt T, Worth R, et al. Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy. *Neurology*. 2015;84(10):1017-1025. doi:10.1212/WNL.0000000000001334

12. Fisher R, Salanova V, Witt T, et al. Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy. *Epilepsia*. 2010;51(5):899-908. doi:10.1111/j.1528-1167.2010.02536.x

13. Velasco AL, Velasco F, Velasco M, Trejo D, Castro G, Carrillo-Ruiz JD. Electrical stimulation of the hippocampal epileptic foci for seizure control: a double-blind, long-term follow-up study. *Epilepsia*. 2007;48(10):1895-1903. doi:10.1111/j.1528-1167.2007.01181.x

14. McLachlan RS, Pigott S, Tellez-Zenteno JF, Wiebe S, Parrent A. Bilateral hippocampal
stimulation for intractable temporal lobe epilepsy: impact on seizures and memory. *Epilepsia*.
2010;51(2):304-307. doi:10.1111/j.1528-1167.2009.02332.x

15. Tyrand R, Seeck M, Spinelli L, et al. Effects of amygdala–hippocampal stimulation on
interictal epileptic discharges. *Epilepsy Research*. 2012;99(1):87-93.
doi:10.1016/j.eplepsyres.2011.10.026

16. Cukiert A, Cukiert CM, Argentoni-Baldochi M, et al. Intraoperative neurophysiological
responses in epileptic patients submitted to hippocampal and thalamic deep brain
stimulation. *Seizure*. 2011;20(10):748-753. doi:10.1016/j.seizure.2011.07.003

17. Skelton HM, Brandman DM, Bullinger K, Isbaine F, Gross RE. Distinct Biomarkers of
ANT Stimulation and Seizure Freedom in an Epilepsy Patient with Ambulatory Hippocampal
Electrocorticography. *Stereotact Funct Neurosurg*. 2023;101(6):349-358.
doi:10.1159/000533680

18. Silva AB, Khambhati AN, Speidel BA, Chang EF, Rao VR. Effects of anterior thalamic
nuclei stimulation on hippocampal activity: Chronic recording in a patient with drug-resistant
focal epilepsy. *Epilepsy & Behavior Reports*. 2021;16:100467.
doi:10.1016/j.ebr.2021.100467

19. Voges BR, Schmitt FC, Hamel W, et al. Deep brain stimulation of anterior nucleus
thalami disrupts sleep in epilepsy patients. *Epilepsia*. 2015;56(8):e99-e103.
doi:10.1111/epi.13045

20. Drane DL, Pedersen NP. Finding the Sweet Spot: Fine-Tuning DBS Parameters to Cure
Seizures While Avoiding Psychiatric Complications. *Epilepsy Curr*. 2019;19(3):174-176.
doi:10.1177/1535759719845326

21. Järvenpää S, Peltola J, Rainesalo S, Leinonen E, Lehtimäki K, Järventausta K.
Reversible psychiatric adverse effects related to deep brain stimulation of the anterior
thalamus in patients with refractory epilepsy. *Epilepsy Behav*. 2018;88:373-379.
doi:10.1016/j.yebeh.2018.09.006

22. Schulz R, Gerloff C, Hummel FC. Non-invasive brain stimulation in neurological
diseases. *Neuropharmacology*. 2013;64:579-587. doi:10.1016/j.neuropharm.2012.05.016

23. Polanía R, Nitsche MA, Ruff CC. Studying and modifying brain function with non-
invasive brain stimulation. *Nat Neurosci*. 2018;21(2):174-187. doi:10.1038/s41593-017-
0054-4

24. Vöröslakos M, Takeuchi Y, Brinyiczki K, et al. Direct effects of transcranial electric
stimulation on brain circuits in rats and humans. *Nat Commun*. 2018;9(1):483.
doi:10.1038/s41467-018-02928-3

25. Grossman N, Bono D, Dedic N, et al. Noninvasive Deep Brain Stimulation via
Temporally Interfering Electric Fields. *Cell*. 2017;169(6):1029-1041.e16.
doi:10.1016/j.cell.2017.05.024

26. Wessel MJ, Beanato E, Popa T, et al. Noninvasive theta-burst stimulation of the human
striatum enhances striatal activity and motor skill learning. *Nat Neurosci*. 2023;26(11):2005-
2016. doi:10.1038/s41593-023-01457-7

27. Acerbo E, Jegou A, Luff C, et al. Focal non-invasive deep-brain stimulation with temporal
interference for the suppression of epileptic biomarkers. *Front Neurosci*. 2022;16:945221.
doi:10.3389/fnins.2022.945221

28. Missey F, Rusina E, Acerbo E, et al. Orientation of Temporal Interference for Non-
invasive Deep Brain Stimulation in Epilepsy. *Front Neurosci*. 2021;15:633988.
doi:10.3389/fnins.2021.633988

29. Botzanowski B, Donahue MJ, Ejneby MS, et al. Noninvasive Stimulation of Peripheral
Nerves using Temporally-Interfering Electrical Fields. *Adv Healthc Mater*.
2022;11(17):e2200075. doi:10.1002/adhm.202200075

30. Carmona-Barrón VG, Fernández del Campo IS, Delgado-García JM, De la Fuente AJ,
Lopez IP, Merchán MA. Comparing the effects of transcranial alternating current and
temporal interference (tTIS) electric stimulation through whole-brain mapping of c-Fos
immunoreactivity. *Front Neuroanat*. 2023;17. doi:10.3389/fnana.2023.1128193

31. Song S, Zhang J, Tian Y, Wang L, Wei P. Temporal Interference Stimulation Regulates
Eye Movements and Neural Activity in the Mice Superior Colliculus. *Annu Int Conf IEEE Eng
Med Biol Soc*. 2021;2021:6231-6234. doi:10.1109/EMBC46164.2021.9629968

32. Missey F, Ejneby MS, Ngom I, et al. Obstructive sleep apnea improves with non-invasive
hypoglossal nerve stimulation using temporal interference. *Bioelectronic Medicine*.
2023;9(1):18. doi:10.1186/s42234-023-00120-7

33. Botzanowski B, Acerbo E, Lehmann S, et al. Controlling focality and intensity of non-
invasive deep brain stimulation using multipolar temporal interference in non-human
primates and rodents. Published online September 6, 2023:2023.09.05.556444.
doi:10.1101/2023.09.05.556444

34. Violante IR, Alania K, Cassarà AM, et al. Non-invasive temporal interference electrical
stimulation of the human hippocampus. *Nat Neurosci*. 2023;26(11):1994-2004.
doi:10.1038/s41593-023-01456-8

35. Medina Villalon S, Paz R, Roehri N, et al. EpiTools, A software suite for presurgical brain
mapping in epilepsy: Intracerebral EEG. *J Neurosci Methods*. 2018;303:7-15.
doi:10.1016/j.jneumeth.2018.03.018

36. IT'IS Database for Thermal and Electromagnetic Parameters of Biological Tissues –
ScienceOpen. Accessed April 15, 2024.
https://www.scienceopen.com/document?vid=a95fbaa4-efd8-429a-a59e-5e208fea2e45

37. Colombet B, Woodman M, Badier JM, Bénar CG. AnyWave: a cross-platform and
modular software for visualizing and processing electrophysiological signals. *J Neurosci
Methods*. 2015;242:118-126. doi:10.1016/j.jneumeth.2015.01.017

38. Roehri N, Pizzo F, Lagarde S, et al. High-frequency oscillations are not better
biomarkers of epileptogenic tissues than spikes. *Ann Neurol*. 2018;83(1):84-97.
doi:10.1002/ana.25124

39. Cavarretta, F., Carnevale, N.T., Tegolo, D. & Migliore, M. Effects of low frequency
electric fields on synaptic integration in hippocampal CA1 pyramidal neurons: implications for
power line emissions. Front. Cell. Neurosci. 2014;8:310. doi:10.3389/fncel.2014.00310.
726

727 40. Migliore R, De Simone G, Leinekugel X, Migliore M. The possible consequences for
728 cognitive functions of external electric fields at power line frequency on hippocampal CA1
729 pyramidal neurons. Eur J Neurosci. 2017 Apr;45(8):1024-1031. doi:10.1111/ejn.13325.
730
731 41. Migliore, M., Novara, G. & Tegolo, D. Single neuron binding properties and the magical
732 number 7. Hippocampus. 2008;18:1122–1130. doi:10.1002/hipo.20471.
733
734 42. Hines, M.L. & Carnevale, N.T. The NEURON Simulation Environment. Neural Comput.
735 1997;9:1179–1209. doi:10.1162/neco.1997.9.6.1179.
736
737 43. Weiss SA, Orosz I, Salamon N, et al. Ripples on spikes show increased phase-amplitude
738 coupling in mesial temporal lobe epilepsy seizure-onset zones. Epilepsia. 2016;57(11):1916-
739 1930. doi:10.1111/epi.13572
740
741 44. Urrestarazu E, Chander R, Dubeau F, Gotman J. Interictal high-frequency oscillations
742 (100-500 Hz) in the intracerebral EEG of epileptic patients. Brain. 2007;130(9):2354-2366.
743 doi:10.1093/brain/awm149. Epub 2007 Jul 11. PMID:17626037.
744
45. Mooij AH, Raijmann RCMA, Jansen FE, Braun KPJ, Zijlmans M. Physiological Ripples
(± 100 Hz) in Spike-Free Scalp EEGs of Children With and Without Epilepsy. *Brain Topogr*.
2017;30(6):739-746. doi:10.1007/s10548-017-0590-y
46. Urrestarazu E, Chander R, Dubeau F, Gotman J. Interictal high-frequency oscillations
(100–500 Hz) in the intracerebral EEG of epileptic patients. *Brain*. 2007;130(9):2354-2366.
doi:10.1093/brain/awm149
47. Mina F, Benquet P, Pasnicu A, Biraben A, Wendling F. Modulation of epileptic activity by
deep brain stimulation: a model-based study of frequency-dependent effects. *Front Comput
Neurosci*. 2013;7. doi:10.3389/fncom.2013.00094
48. Mirzakhalili E, Barra B, Capogrosso M, Lempka SF. Biophysics of Temporal Interference
Stimulation. *Cell Syst.* 2020 Dec 16;11(6):557-572.e5. doi:10.1016/j.cels.2020.10.004.
756
49. Gabriel C, Peyman A, Grant EH. Electrical conductivity of tissue at frequencies below 1
MHz. Phys Med Biol. 2009;54(16):4863.
50. Hill AV, Katz B, Solandt DY. Nerve excitation by alternating current. *Proceedings of the
Royal Society of London Series B - Biological Sciences*. 1997;121(821):74-133.
doi:10.1098/rspb.1936.0053
51. Karimi F, Cassarà AM, Capstick M, Kuster N, Neufeld E. Safety of non-invasive brain
stimulation in patients with implants: a computational risk assessment. J Neural Eng.
2024;21(6):066005. doi:10.1088/1741-2552/ad8efa.
52. Jacobs J, Golla T, Mader M, et al. Electrical stimulation for cortical mapping reduces the
density of high frequency oscillations. *Epilepsy Research*. 2014;108(10):1758-1769.
doi:10.1016/j.eplepsyres.2014.09.022
53. Paschen E, Elgueta C, Heining K, et al. Hippocampal low-frequency stimulation prevents
seizure generation in a mouse model of mesial temporal lobe epilepsy. Huguenard JR,
Kadam SD, eds. *eLife*. 2020;9:e54518. doi:10.7554/eLife.54518
54. Luff CE, Dzialecka P, Acerbo E, Williamson A, Grossman N. Pulse-width modulated
temporal interference (PWM-TI) brain stimulation. *Brain Stimulation*. 2024;17(1):92-103.
doi:10.1016/j.brs.2023.12.010

55. Acerbo E, Botzanowski B, Dellavale D, et al. Improved Temporal and Spatial Focality of
Non-invasive Deep-brain Stimulation using Multipolar Single-pulse Temporal Interference
with Applications in Epilepsy. Published online January 14, 2024:2024.01.11.575301.
doi:10.1101/2024.01.11.575301

56. Cukiert A, Cukiert CM, Burattini JA, Mariani PP, Bezerra DF. Seizure outcome after
hippocampal deep brain stimulation in patients with refractory temporal lobe epilepsy: A
prospective, controlled, randomized, double-blind study. *Epilepsia*. 2017;58(10):1728-1733.
doi:10.1111/epi.13860

57. Cukiert A, Cukiert CM, Burattini JA, Mariani PP. Long-term seizure outcome during
continuous bipolar hippocampal deep brain stimulation in patients with temporal lobe
epilepsy with or without mesial temporal sclerosis: An observational, open-label study.
Epilepsia. 2021;62(1):190-197. doi:10.1111/epi.16776

58. Velasco F, Velasco M, Velasco AL, Menez D, Rocha L. Electrical stimulation for
epilepsy: stimulation of hippocampal foci. *Stereotact Funct Neurosurg*. 2001;77(1-4):223-
227. doi:10.1159/000064610

59. Karakis I, Lynam C, Taraschenko O, Staikova E, Drane DL. Concurrent EEG monitoring
helps interpret neuropsychological testing results in patients with epilepsy. *Epilepsy Behav*.
2020;111:107275. doi:10.1016/j.yebeh.2020.107275

60. Glennon JM, Weiss-Croft L, Harrison S, Cross JH, Boyd SG, Baldeweg T. Interictal
epileptiform discharges have an independent association with cognitive impairment in
children with lesional epilepsy. *Epilepsia*. 2016;57(9):1436-1442. doi:10.1111/epi.13479

61. Dinkelacker V, Xin X, Baulac M, Samson S, Dupont S. Interictal epileptic discharge
correlates with global and frontal cognitive dysfunction in temporal lobe epilepsy. *Epilepsy*
Behav. 2016;62:197-203. doi:10.1016/j.yebeh.2016.07.009

62. Drane DL, Ojemann JG, Kim MS, et al. Interictal epileptiform discharge effects on
neuropsychological assessment and epilepsy surgical planning. *Epilepsy Behav*.
2016;56:131-138. doi:10.1016/j.yebeh.2016.01.001

Supplementary Figures:

Figure S1. Center-by-center analysis.

824
825   **Figure S2. Single patient interictal epileptiform discharge analysis.**
826

Figure S3. Single patient ripples analysis.

829
830 **Figure S4. Single patient fast ripples analysis.**
831

832
833 **Figure S5. Simulations of the TI stimulation for different carrier frequencies.** Measurement across a 100Ohm resistor
834 of the output current as a function of the frequency applied via the Keysight and DS5. The relationship shows no significant
835 applied current difference between lower carrier values (1000Hz) and higher carrier values (9000Hz) for a biological
836 impedance (patient head – blue trace), effectively demonstrating the devices show no frequency roll-off effects from the
837 spectrum of carrier values and impedances that were used in the study.
838

839
840 **Figure S6. Recorded AM amplitude and calculated AM EF along an sEEG electrode targeting the hippocampus.**
841 The distribution of the maximum modulation amplitude and the maximum modulation electric field will differ. (**right panel**)
842 The experimentally measured maximum of the AM corresponds well to the maximum of the AM electric field (computed
843 as the modulation magnitude of the difference of potential between two contacts) at the focus of the epilepsy in the
844 hippocampus. (**right panel**) The source of the neuromodulation effect is assumed to be the maximum AM field exposure.

845
Figure S7. Theoretical Field Enhancement around sEEG electrodes. We characterize the electric field enhancement
around the implanted SEEG electrodes during transcranial stimulation and determine the expected impact to be negligible.
(left panel - top) Currents injected by transcranial stimulation can leverage low-impedance pathways through metallic
SEEG contacts, and field lines bend near metallic surfaces such that tangential field components vanish. This not only
results in local field enhancement[51] near contact edges and bridging currents between neighboring contacts, but also in
alignment of the two TI fields, resulting in an associated modulation magnitude increase. **(left panel – bottom)** The
enhancement of the field was computed and found to be 2 to 7.2x the size of the incident TI modulation magnitude but
decayed to the level of the surrounding AM field within 400 μm. Glial sheath formation around implanted intracranial
electrodes is estimated to range from 150 to 300 μm. **(middle panels)** Visualization of the enhancement in a patient
model – horizonal slice: the TI field near SEEG contacts in the hippocampus is depicted and plotted along the green
trajectory. Several highly localized spots of AM enhancement are apparent. **(right panels)** Similar enhancement is evident
in a sagittal cross-section. As can be seen in the middle and right panels, the entire hippocampus (left side) is covered by
high AM exposure. The suppression of epileptic biomarkers at the brain network level, as observed in the current study,
is unlikely to be caused by the highly localized subthreshold modulation near electrode contacts, considering that no
significant enhancement is present outside the typical glial sheath thickness.
861
862

Patient	Age	Sex	Center	Head Ø	N° of electrodes	SOZ	Day PI
P1	35-39	F	SAUH	59	8	Right temporal lobe	6
P2	40-44	M	SAUH	61	13	Left Insular lobe	6
P3	35-39	M	SAUH	60	11	Left temporal lobe	6
P4	45-49	F	SAUH	60	8	Bi-temporal lobes	6
P5	40-44	M	SAUH	61	8	Left temporal lobe	6
P6	35-39	M	EMORY	54	10	Bi temporal lobe	7
P7	25-29	M	EMORY	60	13	Left parietal lobe	7
P8	35-39	M	EMORY	58	18	Left temporal lobe	7
P9	30-34	F	INN-SU	58	8	Left temporal lobe	8
P10	40-44	M	INN-SU	61	6	Left temporal lobe	7
P11	45-49	F	INN-SU	60	7	Right temporal lobe	6
P12	25-29	M	SAUH	61	12	Right temporal lobe	6
P13	30-34	F	SAUH	60	14	Left temporal lobe	6

863
864 **Table 1. Participant characteristics.** Ages are displayed in ranges of 5 years to ensure anonymization of the patients.
865
866
867